Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;37(4):283-94.
doi: 10.1007/s40264-014-0150-2.

The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010

Keith B Hoffman  1 , Mo Dimbil, Colin B Erdman, Nicholas P Tatonetti, Brian M Overstreet
Affiliations

The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010

Keith B Hoffman et al. Drug Saf. 2014 Apr.

Erratum in

  • Drug Saf. 2014 May;37(5):381

Abstract

Background: The United States Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS) consists of adverse event (AE) reports linked to approved drugs. The database is widely used to support post-marketing safety surveillance programs. Sometimes cited as a limitation to the usefulness of FAERS, however, is the 'Weber effect,' which is often summarized by stating that AE reporting peaks at the end of the second year after a regulatory authority approves a drug. Weber described this effect in 1984 based upon a single class of medications prescribed in the United Kingdom. Since that time, the FDA has made a concerted effort to improve both reporting and the database itself. Both volume and quality of AE reporting has dramatically improved since Weber's report, with an estimated 800,000 yearly reports now being logged into FAERS.

Objective: The aim of this study was to determine if current FAERS reporting follows the trend described by Weber.

Methods: Sixty-two drugs approved by the FDA between 2006 and 2010 were included in this analysis. Publicly available FAERS data were used to assess the 'primary suspect' AE reporting pattern for up to a 4-year period following each drug's approval date.

Results: A total of 334,984 AE reports were logged into FAERS for the 62 drugs analyzed here. While a few of the drugs demonstrated what could be considered 'Weber effect' curves, a majority of the drugs showed little evidence for the effect. In fact, the general AE reporting pattern observed in this study appears to consist simply of increasing case counts over the first three quarters after approval followed by relatively constant counts thereafter.

Conclusions: Our results suggest that most of the modern adverse event reporting into FAERS does not follow the pattern described by Weber. Factors that may have contributed to this finding include large increases in the volume of AE reports since the Weber effect was described, as well as a concerted effort by the FDA to increase awareness regarding the utility of post-marketing AE reporting.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Drugs approved in 2006
Fig. 2
Fig. 2
Drugs approved in 2007
Fig. 3
Fig. 3
Drugs approved in 2008
Fig. 4
Fig. 4
Drugs approved in 2009
Fig. 5
Fig. 5
Drugs approved in 2010
Fig. 6
Fig. 6
The average of all ‘all reporters’ for the 62 drugs
Fig. 7
Fig. 7
The average of all ‘healthcare professional reporters’ for the 62 drugs
Fig. 8
Fig. 8
Within-drug comparison of normalized case counts compared with a hypothetical linear Weber-like decrease in case counts from quarter 8 after approval to quarter 16
See this image and copyright information in PMC

References

    1. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003;18(1):57–60. doi: 10.1046/j.1525-1497.2003.20130.x. - DOI - PMC - PubMed
    1. FDA. Follow-Up to the November 2009 Early Communication about an Ongoing Safety Review of Sibutramine, Marketed as Meridia. 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa.... Accessed Feb 2014.
    1. Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ (Clin Res Ed). 2001;323(7309):359. doi: 10.1136/bmj.323.7309.359. - DOI - PMC - PubMed
    1. FDA. Safety Information: Vioxx (rofecoxib). 2002. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuma.... Accessed Feb 2014.
    1. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA, J Am Med Assoc. 2002;287(17):2215–2220. doi: 10.1001/jama.287.17.2215. - DOI - PubMed

Publication types

MeSH terms